NASDAQ: RANI - Rani Therapeutics Holdings, Inc.

Rentabilidad a seis meses: -70.01%
Sector: Healthcare

Calendario de promoción Rani Therapeutics Holdings, Inc.


Acerca de la empresa

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies.

Más detalles
Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.

Выручка 0.000979
EBITDA -0.0261
Число акций ао 0.02551 млрд
P/S 4296.54
P/BV -43.53
EV/EBITDA -165.09
Цена ао 3.18
ISIN US7530181004
Сайт https://www.ranitherapeutics.com
Валюта usd
IPO date 2021-07-30
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Cambio de precio por día: 0% (2.12)
Cambio de precio por semana.: -9.79% (2.35)
Cambio de precio por mes: -10.55% (2.37)
Cambio de precio en 3 meses.: -37.09% (3.37)
Cambio de precio en seis meses: -70.01% (7.07)
Cambio de precio por año: +5.47% (2.01)
Cambio de precio en 3 años.: -86.82% (16.09)
Cambio de precio desde principios de año.: +5.47% (2.01)

Subestimación

Nombre Significado Calificación
P/S 0 0
P/BV 3.31 5
P/E 0 0
EV/EBITDA -1.65 0
Total: 3.13

Eficiencia

Nombre Significado Calificación
ROA, % -58.65 0
ROE, % -264.03 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.4611 10
Total: 7.8

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 175.79 10
Rentabilidad Ebitda, % 150.1 10
Rentabilidad EPS, % -6.2 0
Total: 6.6

Instituciones Volumen Compartir, %
Vanguard Group Inc 668347 2.57
Nan Fung Group Holdings Limited 493584 1.9
United Services Automobile Association 481300 1.85
Alphabet Inc. 448492 1.72
Bank of America Corporation 114259 0.44
Geode Capital Management, LLC 113629 0.44
Blackrock Inc. 63583 0.24
Lasry, Marc 62887 0.24
Alpha Square Group S, LLC 58946 0.23
King Luther Capital Management 56129 0.22

ETF Compartir, % Rentabilidad del año, % Dividendos, %
Dimensional International Core Equity 2 ETF 0.00033 17.713295799047 3.69996
Dimensional International Small Cap ETF 0.00065 18.692449355433 3.34747
Dimensional International Small Cap Value ETF 0.00059 18.789944610141 4.55441



Supervisor Título profesional Pago año de nacimiento
Mr. Mir A. Imran Executive Chairman 80k 1956 (68 años)
Mr. Talat Imran CEO & Director 450k 1982 (42 año)
Mr. Svai S. Sanford Chief Financial Officer 416k 1970 (54 año)
Dr. Mir Hashim Chief Scientific Officer 416k 1960 (64 año)
Mr. Eric Groen General Counsel N/A 1971 (53 año)
Ms. Bella Vazquez Vice President of Human Resources N/A
Ms. Kate McKinley M.B.A. Chief Business Officer N/A 1977 (47 años)
Ms. Arvinder Dhalla Vice President of Clinical Development N/A

DIRECCIÓN: United States, San Jose. CA, 2051 Ringwood Avenue - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.ranitherapeutics.com